Lenalidomide is under clinical development by Starton Therapeutics and currently in Phase II for Relapsed Multiple Myeloma. According to GlobalData, Phase II drugs for Relapsed Multiple Myeloma have a 37% phase transition success rate (PTSR) indication benchmark for progressing into Phase III. GlobalData’s report assesses how Lenalidomide’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.
Smarter leaders trust GlobalData
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
Lenalidomide overview
Lenalidomide is under development for the treatment of relapsed and refractory multiple myeloma and chronic lymphocytic leukemia (CLL). It is administered through transdermal and subcutaneous route and acts by targeting protein cereblon (CRBN). The drug candidate is developed based on permeation enhanced transdermal technology (PETT) platform.
It was also under development for the treatment of myelodysplastic syndrome and mantle cell lymphoma.
Starton Therapeutics overview
Starton Therapeutics (Starton), is a biotechnology company that discovers and develops drugs for the treatment of hematological malignancies. The company is investigating Star-LLD to treat chronic lymphocytic leukemia (CLL) and multiple myeloma (MM). It is also evaluating STAR-OLZ, to control PARP inhibitor and chemotherapy-induced nausea and vomiting; and STAR-RK against nerve disorders. Starton applies transdermal technology, where an adhesive patch is used to deliver medicine through the skin. The company develops products in the therapeutic areas of hematology and oncology. Starton is headquartered in Paramus, New Jersey, the US.
For a complete picture of Lenalidomide’s drug-specific PTSR and LoA scores, buy the report here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in clinical development (PTSR), as well as how likely the drug will be approved (LoA). This is based on a combination of machine learning and a proprietary algorithm to process data points from various databases found on GlobalData’s Pharmaceutical Intelligence Center.
